# US 2024/0302389 A1 · Cardiovascular Risk Evaluations Using a Risk Parameter That Includes an HDL and Inflammatory Biomarker Interaction Parameter

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0302389 A1
- Document ID: US20240302389A1
- Status: Published application
- Kind: A1
- Application number: 18/661,491
- Filed: 2024-05-10
- Published: 2024-09-12
- Earliest claimed: 2014-09-11
- Assignees: LipoScience, Inc.
- Applicants: LipoScience, Inc.
- Inventors: James D. Otvos; Irina Y. Shalaurova
- Web page: https://patentgrep.com/patent/US20240302389A1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- G01R 33/465: applied to biological material, e.g. in vitro testing
- G01N 2570/00: Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
- G01N 2800/32: Cardiovascular disorders
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Methods, systems and circuits evaluate a subject's CVD risk using a risk parameter that includes at least one HDL and inflammatory biomarker interaction parameter. The inflammatory biomarker may optionally comprise NMR derived measurements of GlycA from at least one biosample of the subject. The risk parameter may be gender-specific.

## Claims

### Claim 1

A method of determining a risk parameter for cardiovascular disease or events, comprising:
obtaining measurements of HDL particles and at least one inflammatory biomarker in a biosample from a subject;
determining concentrations for at least one individual HDL particle size subclass and the at least one inflammatory biomarker, based on the measurements; and
programmatically calculating a risk parameter ((HxI)CVD) of the subject using at least the concentrations for the at least one subclass of HDL particle and the at least one inflammatory biomarker.

### Claim 2 (depends on 1)

The method of claim 1, further comprising determining a subject's risk of having and/or developing CVD based, at least in part, on the (HxI)CVD risk parameter number.

### Claim 3 (depends on 1)

The method of claim 1, wherein the biosample is an in vitro blood plasma or serum sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein concentrations are determined for HDL particle size subclasses cH1-cH8.

### Claim 5 (depends on 1)

The method of claim 1, wherein the determining step and/or the calculating step is carried out using at least one processor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the at least one individual HDL particle size subclass comprises at least one of the following:
(i) cH1 having a diameter in the range of 7.0-7.6 nm;
(ii) cH8 having a diameter in the range of 11.5-13.5 nm.

### Claim 7 (depends on 6)

The method of claim 6, wherein (HxI)CVD is:
(HxI)CVD=c1(cH1)+c2(INFLAM)+c3(INTERH1); or
(HxI)CVD=c4(cH8)+c5(INFLAM)+c6(INTERH8)
wherein INFLAM is the concentration of the at least one inflammatory biomarker, INTERH1=INFLAM*cH1, INTERH8=INFLAM*cH8, and wherein “c1-c6” represent coefficients from a mathematical model of CVD events in a study population for the associated risk parameter.

### Claim 8 (depends on 7)

The method of claim 7, wherein (HxI)CVD is gender-specific.

### Claim 9 (depends on 8)

The method of claim 8, wherein utilizing the concentration of an HDL-P subclass cH1, having an average diameter in the range of 7.0-7.6 nm, with GlycA as the inflammatory biomarker to generate (HxI)CVD provides a male-specific HDL-inflammation multimarker.

### Claim 10 (depends on 8)

The method of claim 8, wherein utilizing the concentration of an HDL-P subclass cH8, having an average diameter in the range of 11.5-13.5 nm, with GlycA as the inflammatory biomarker to generate (HxI)CVD provides a female-specific HDL-inflammation multimarker.

### Claim 11 (depends on 1)

The method of claim 1, further comprising electronically providing the calculated (HxI)CVD to a medical professional and/or patient report.

### Claim 12 (depends on 11)

The method of claim 11, further comprising prescribing, recommending, or deciding upon a treatment for the subject based at least in part on the calculated (HxI)CVD.

### Claim 13 (depends on 1)

The method of claim 1, wherein the obtaining measurements comprises obtaining an NMR signal from the biosample to determine NMR-derived concentration measurements of HDL particle subclasses and/or the inflammatory biomarker.

### Claim 14 (depends on 1)

The method of claim 1, wherein the determining further comprises deconvolving a composite NMR spectrum of a fitting region of a plasma sample of a subject using a defined deconvolution model with at least eight HDL-P subclasses.

### Claim 15 (depends on 1)

The method of claim 1, wherein the inflammatory biomarker comprises GlycA, and wherein the at least one interaction parameter includes one interaction parameter defined by GlycA concentration multiplied by at least one HDL-P subclass concentration, wherein the at least one HDL-P subclass demonstrates gender specificity for CVD events in a study population for the associated risk parameter.

### Claim 16

A system for determining a risk parameter for cardiovascular disease or events, comprising:
a component for obtaining measurements of HDL particles and at least one inflammatory biomarker in a biosample from a subject;
a component for determining concentrations for at least one individual HDL particle size subclass and the at least one inflammatory biomarker, based on the measurements; and
a component for programmatically calculating a risk parameter ((HxI)CVD) of the subject using at least the concentrations for the at least one subclass of HDL particle and the at least one inflammatory biomarker.

### Claim at position 17

17-25. (canceled)

### Claim 26 (depends on 1)

A computer program product for determining a risk parameter for cardiovascular disease or events according to the method of claim 1.

### Claim 27

A computer program product for determining a risk parameter for cardiovascular disease or events, the computer program product comprising:
a non-transitory computer readable storage medium having computer readable program code embodied in the medium, the computer-readable program code comprising:
computer readable program code that obtains concentration measurements for at least eight subclasses of HDL-P in a blood plasma or serum sample and at least one inflammatory biomarker, and
computer readable program code that calculates a risk parameter ((HxI)CVD) comprising at least one interaction parameter.

### Claim at position 20

28-37. (canceled)
